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Abstract 
Sepsis is a systemic inflammatory response syndrome in the presence of suspected or proven infection, and it may progress 
to or encompass organ failure (severe sepsis) and hypotension (septic shock).  Clinicians possess an arsenal of supportive 
measures to combat severe sepsis and septic shock, and some success, albeit controversial, has been achieved by using low 
doses of corticosteroids or recombinant human activated protein C. However, a truly effective mediator-directed specific 
treatment has not been developed yet. Treatment with low doses of corticosteroids or with recombinant human activated 
protein C remains controversial and its success very limited. Attempts to treat shock by blocking LPS, TNF or IL-1 were 
unsuccessful, as were attempts to use interferon-gamma or granulocyte colony stimulating factor. Inhibiting nitric oxide 
synthases held promise but met with considerable difficulties. Scavenging excess nitric oxide or targeting molecules 
downstream of inducible nitric oxide synthase, such as soluble guanylate cyclase or potassium channels, might offer other 
alternatives. 
Key words: sepsis, NOS, nitric oxide, corticosteroids, protein C 
 
Introduction 
Sepsis may be defined as a systemic inflammatory 
response syndrome in the presence of suspected or 
proven infection. It is classified as severe sepsis if there is 
organ dysfunction, and as septic shock if severe shock is 
associated with hypotension despite fluid resuscitation. 
Sepsis is initiated by severe infections and precipitated by 
interactions between the pathogenic organism, the host 
immune and inflammatory responses, and coagulation 
processes [1]. The mortality rate from severe sepsis is 25-
30% [2] and from septic shock it is 40-70% [3]. Though 
the rate of mortality due to septic shock has declined from 
62% in the first part of the twentieth century to 56% by 
the year 2000 [4], its incidence has been rising [5,6]. 
Factors that could contribute to this rise include the 
increase in life expectancy and in the number of 
immunocompromised individuals, the more widespread 
use of invasive medical procedures and 
immunosuppressive therapy, the increase in microbial 
resistance, and the rising incidence of infection due to 
organisms other than bacteria. Though part of the 
reported increase in septic shock could be an artifact of 
the improvement in recognition and recording of the 
condition [7,8], mortality rates remain unacceptably high. 
Despite intense research, progress in therapy has clearly 
been inadequate, and it is for good reason that clinical 
trials on sepsis have been called “the graveyard of 
pharmaceutical companies.” An arsenal of supportive 
measures is used to treat septic shock, but specific 
treatment that targets mediators of shock relies mostly on 
corticosteroids and recombinant human activated protein 
C [9,10]. 
 
Mediator-directed treatment 
Because a runaway inflammatory response is a major 
aspect of sepsis, most prospective therapies targeted 
mediators of inflammation. However, most strategies 
failed to improve survival in clinical trials, as described in a 
review [11]. One of the earliest therapeutic targets was 
the endotoxin of Gram-negative bacteria (LPS), but clinical 
trials employing blockade of LPS with specific antibodies 
failed to show significant benefit [12]. Another approach 
tried to capitalize on the anti-inflammatory properties of 
corticosteroids by administering large doses to counteract 
the runaway immune responses [13], but a later study 
failed to demonstrate significant benefits for this approach 
[14]. By contrast, prolonged administration of low doses 
of corticosteroids as a hormonal replacement therapy to 
compensate for the lowered level of cortisol in many 
sepsis patients were recently shown to be beneficial [5]. 
 
Another well-known target is the potent 
proinflammatory cytokine, TNF, which is elevated in 
sepsis. Though animal experiments were promising, 
clinical trials failed to show any benefit for this approach 
[15,16]. Blocking IL-1 suffered a similar fate [17]. 
Attempts to reverse the immune suppression that occurs 
in sepsis by using interferon (IFN)- or granulocyte colony 
stimulating factor (G-CSF) were also unsuccessful [18]. 
Yet another approach targeted the crosstalk between the 
coagulation and inflammatory systems; however, clinical 
trials using TF (tissue factor) antagonists, tissue factor-
pathway inhibitor (TFPI) [19,20], or antithrombin (AT)-III 
[21] could not demonstrate significant benefit. 
 
Corticosteroids
The anti-inflammatory and hemodynamic effects of 
corticosteroids (glucocorticoids) have been known for a 
long time. They inhibit the production of inflammatory 
cytokines, prostaglandins, leukotrienes, and nitric oxide. 
Indeed, one of the homeostatic physiologic responses to 
sepsis is an increased level of stress hormones such as 
cortisol (though reduced responsiveness to corticotropin is 
also frequent). However, a meta-analysis of clinical trials 
showed that large doses of corticosteroids, despite their 
strong anti-inflammatory action, do not improve survival 
but may actually be harmful [22]. From these findings, 
and from the knowledge that adrenal insufficiency is part 
of sepsis, developed the notion of using physiologic doses 
of corticosteroids as adrenal replacement therapy in 
infection, sepsis, and septic shock. 
  
A systematic review of clinical trials [5] concluded that 
long courses of low dose corticosteroids reduce mortality. 
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Another systematic study [23] recommended low dose 
corticosteroids for septic shock and counseled against high 
doses, except perhaps in some specific conditions; 
corticosteroids were not recommended for sepsis in the 
absence of shock. It is noteworthy that corticosteroid 
treatment was shown to be more beneficial for the more 
severely ill patients [24]. However, the use of 
corticosteroids in shock remained controversial [11]. The 
results of the recent CORTICUS trial, an international, 
prospective, randomized, double-blind, placebo controlled 
study, concluded that corticosteroid treatment did not 
reduce mortality, irrespective of ACTH responsiveness 
[25]. Though that report stated that the use of 
hydrocortisone was not associated with a higher incidence 
of superinfection, a more recent examination has revealed 
more superinfections and new sepsis and septic shock in 
steroid treated patients (Charles Sprung, personal 
communication). 
 
Activated protein C 
Pro-inflammatory cytokines released in response to 
infection can initiate coagulation by activating tissue 
factor. Thrombin, which converts fibrinogen to fibrin and 
performs other functions in the coagulation process, can 
stimulate several inflammatory pathways, and moreover, 
coagulation and inflammation reciprocally amplify each 
other [26], potentially leading to organ failure. 
 
Protein C is an important physiological anticoagulant 
[27]. Once activated by the thrombin-thrombomodulin 
complex, it acts to inhibit blood coagulation by 
proteolytically inactivating factors Va and VIIIa [28]. 
Moreover, activated protein C (APC) inhibits inflammatory 
cytokine production and limits the rolling of monocytes 
and neutrophils on injured endothelium [29]. APC is 
downregulated in sepsis, [30], which implies that it could 
be a useful treatment. 
 
One landmark in the quest for a treatment for severe 
sepsis was a randomized, double-blind, placebo-controlled, 
multicenter trial, known as the PROWESS trial, conducted 
on 1690 sepsis patients who were at high risk of death 
[2]. This trial showed that rhAPC (recombinant human 
APC) reduces the absolute risk of death by 6.1%, and that 
although treatment was associated with a greater risk of 
bleeding, the benefits outweigh the increased bleeding 
risks. This study, however, has been criticized on 
methodological grounds [31,32]; the efficacy of rhAPC and 
the risk of bleeding have also been questioned [31-33]. 
Quite likely it is for these reasons that treatment with 
rhAPC has not been widely adopted by physicians [10], 
not to mention its extremely high cost [10,11]. 
Noteworthy is that rhAPC should not be used for adults 
with a low risk of death [34], and a recent, large, 
randomized, placebo-controlled study showed no benefit 
for rhAPC in children [35]. A very recent analysis [36] of 
several clinical trials on rhAPC did not come out in support 
of this treatment. It concluded that even in severely ill 
adult sepsis patients at high risk of death, for whom this 
treatment is approved, there is only weak evidence to 
support its use. 
 
Despite this controversy, rhAPC remains on the table, 
and an animal study published during the preparation of 
this manuscript gave indications that showed that the 
bleeding risk associated with this therapy may be 
overcome. By using a variant of APC with greatly reduced 
anticoagulant properties in a mouse model of sepsis, 
mortality was reduced without increasing the risk of 
bleeding [37]. Further research is needed to determine 
whether this strategy would be effective in humans. 
 
Targeting nitric oxide synthases 
Following the discovery that nitric oxide is an important 
endogenous regulator of vascular tone [38-40], its 
importance in inflammatory and septic shock became 
evident. This highly reactive radical is produced by three 
different nitric oxide synthases (NOS). Neuronal nitric 
oxide (nNOS) and endothelial nitric oxide (eNOS) are 
constitutive enzymes that function in homeostatic 
processes such as neurotransmission and vascular tone, 
respectively, by producing small amounts of NO in 
response to increases in intracellular calcium. In contrast, 
iNOS is an inducible enzyme that is usually synthesized 
only in response to inflammation. Unlike the other two 
NOS, iNOS produces large amounts of NO for long periods 
of time [41]. 
 
Because NO is produced from L-arginine, its production 
can be inhibited by competitive L-arginine analogues, such 
as NG-monomethyl-L-arginine (L-NMMA), NG-nitro-L-
arginine (L-NNA) and NG-nitro-L-arginine methyl ester (L-
NAME). NOS inhibitors can prevent, revert, or at least 
minimize hypotension in shock induced by LPS, TNF, IL-1, 
IL-2 or hemorrhage [42-47]. NOS inhibition also elevates 
blood pressure and systemic vascular resistance in septic 
shock patients [48-51]. But NOS inhibition has limited 
therapeutic potential because it is associated with a 
progressive fall in cardiac output, amplified organ 
dysfunction, and even increased mortality [51-56]. In one 
phase III clinical trial, NOS inhibition increased mortality in 
septic patients despite its beneficial effects on blood 
pressure and vascular resistance [49]. General inhibition 
of NOS could be inappropriate for treatment of septic 
shock because eNOS might provide some protection 
against shock. This is clearly shown by the finding that 
transgenic expression of eNOS can partially protect mice 
against endotoxemia and polymicrobial sepsis [57,58]. 
This dichotomous effect of NO places a hurdle in the way 
of developing NOS inhibitors as a treatment for shock, and 
so attempts were made to overcome it by using specific 
iNOS inhibitors. 
 
The effects of specific iNOS inhibition on organ function 
are somewhat controversial, but it does not seem to lead 
to deleterious effects of the same degree as those caused 
by general NOS inhibition. Moreover, iNOS inhibition 
prevented or reverted circulatory failure in all the reports 
[59]. Unfortunately, though iNOS inhibition seemed a 
promising therapeutic strategy, experiments on iNOS-
deficient mice indicated otherwise. Not only were these 
mice not protected against endotoxemia, sepsis or TNF-
induced shock, they even suffered higher mortality rates in 
some studies [60-64]. 
 
Clearly, iNOS inhibitors and iNOS deficiency do not have 
the same effects. It is conceivable that during iNOS 
inhibition the anti-apoptotic or anti-oxidative effects of 
some residual NO may provide some benefit [65,66]. 
Alternatively, iNOS inhibitors could have additional 
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pharmacological effects unrelated to iNOS inhibition, as 
exemplified by the anti-oxidative effects of S-methyl-
isothiourea [67], and the inhibition of catalase by 
aminoguanidine [68], both of which are iNOS inhibitors. 
  
Simple specific iNOS inhibition does not seem to be a 
valid approach to treating shock, because it does not 
always diminish organ damage or mortality in 
experimental endotoxic or septic shock. Thus it would be 
more reasonable to selectively modulate the downstream 
targets of NO that play important roles in the hypotensive 
effects of NO. 
 
Scavenging NO 
An alternative to inhibiting iNOS, especially that no 
specific inhibitor for it is available, is to scavenge excess 
NO. This could also have the advantage of preserving 
some NO at its production locations, where it can perform 
normal physiological functions.  Several NO scavengers 
have been evaluated with some positive results in different 
animal models of shock [69-72].  One interesting NO 
scavenger, pyridoxalated hemoglobin polyoxyethylene 
(PHP), has been evaluated in distributive shock. Because 
the study recruited SIRS patients while excluding those 
with significant cardiac disease, burns or trauma, and 
those who were at risk of dying shortly from an underlying 
condition, the results are relevant to sepsis. In that study, 
PHP raised blood pressure and reduced vasopressor and 
ventilation needs without causing organ damage or 
adversely effecting cardiac output or survival [73]. PHP 
has entered phase III clinical trials and the results are 
expected to be published soon (Gary Kinasewitz, personal 
communication). 
 
Targets downstream of iNOS 
Soluble guanylate cyclase (sGC) 
Binding of NO to sGC, considered its main 
cardiovascular “receptor”, leads to accumulation of cGMP, 
which in turn leads to vascular relaxation, myocardial 
depression, and inhibition of platelet aggregation and 
adhesion [74]. This indicates that the cGMP pathway 
might be a potential target for treatment of shock. 
Inhibiting cGMP production with methylene blue (MB) 
protects mice against experimental shock induced by TNF 
[61], but not against endotoxemia [75]. Analogously, 
infusion of MB in humans suffering septic shock reverses 
hypotension, but does not change the overall mortality 
rate [76-79]. It has been speculated that its protective 
effects could be due to effects on oxidative stress that are 
not sGC-dependent [65]. 
 
K+ channels 
K+ channels play an important role in regulating 
membrane potential, and thus hyperpolarization and 
relaxation of vascular smooth muscle cells. Because NO 
may activate K+ channels both sGC-dependently and sGC-
independently [80-83], inhibition of K+ channels might 
offer an alternative strategy for treatment of shock. 
 
In the vasculature, the most important K+ channel 
subclasses that are involved in the action of various 
endothelium-derived relaxing factors are the ATP-sensitive 
KATP channel and the large conductance calcium-
activated BK channel. KATP channels have long been 
suspected of playing the most important role in septic 
shock [84,85]. They are activated by decreased ATP, 
increased lactate, and acidosis, all of which characterize 
sepsis. In addition, they may also be activated by NO, 
prostacyclin (PGI2), and the recently identified vasodilator, 
H2S [83,84,86]. In many endotoxic animal models, 
inhibiting KATP by parenteral glibenclamide could partially 
return hypotension and vascular hyporesponsiveness to 
normal [87-90]. However, glibenclamide did not restore 
responsiveness in another animal study [91], or in a 
recent clinical trial [92]. Failure in the clinical trial might 
have been due to administration of the drug by the enteric 
route, or to the mild lactic acidosis in the enrolled patients 
[93]. In any event, these results indicate that KATP 
inhibition might not be the solution for septic shock. 
 
BK channels are probably the most important channels 
involved in NO-dependent vascular relaxation [82,83]. NO 
may activate BK channels sGC-dependently through 
phosphorylation by cGMP-dependent protein kinase, as 
well as directly via S-nitrosation without requiring cGMP 
[81,94,95]. BK channels are also targeted by other 
potential vasodilators, including H2O2 and 
epoxyeicosatrienoic acids (EETs) [96-98]. These results 
indicate that inhibiting BK channels could be useful in 
treatment of shock. Unfortunately, most of the few 
published animal studies have not used specific BK-
inhibitors, but rather tetraethylammonium (TEA), a non-
specific inhibitor of BK, KATP and certain voltage-gated KV 
channels. Though TEA neither improved blood pressure 
nor decreased mortality in one animal study [99], it 
successfully restored vascular responsiveness in another 
[91], and in an experimental human endotoxemia study 
[100]. But very recently Cauwels et al., using various 
inhibitors, including iberiotoxin and apamin, which are 
specific for BK channels and small conductance calcium-
dependent SK channels, respectively, showed that both of 
these channels are involved in mouse models of TNF- and 
LPS-induced shock [75]. This indicates that these channels 
could be potential targets for treatment of septic shock. 
 
Conclusions
Despite decades of research, there have been very few 
mediator-specific treatments that consistently improve 
survival of sepsis patients. Corticosteroids and activated 
protein C have been in clinical use and are claimed to save 
lives, but considerable controversy surrounds their efficacy 
and side effects. Clinicians still have to rely in most cases 
on conventional supportive measures to save patients’ 
lives. High hopes were set for NOS inhibition, but this 
approach was not successful. Inhibition of iNOS may 
provide better results, but more specific iNOS inhibitors 
would be needed before this approach can be tested in 
clinical trials. Alternatively, NO scavengers such as PHP 
could be considered for more testing in animals and in 
human trials as scavengers of excessive NO. Otherwise, 
focus can be shifted to downstream targets of NO instead 
of trying to interfere with production of NO, which is 
clearly a Janus-faced molecule in septic shock. 
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